OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate.  OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials.

GJE provided OncoImmunity AS with IP-related due diligence support during the acquisition and continues to manage the company’s patent portfolio. The GJE team is led by partner Matt Hoyles.

To read the full press release, please follow this link.